Renovaro, Inc (Nasdaq: RENB) has launched the Flamingo cancer detection platform, which utilizes AI to analyze cell-free DNA data for early cancer diagnostics. The company aims to accelerate precision and personalized medicine for longevity through AI and biotechnology platforms. RenovaroCube, a molecular data science company, has developed an AI platform for early cancer detection and monitoring treatment efficacy. RenovaroCube plans to acquire 100% ownership of Cyclomics, a company specializing in liquid biopsies using proprietary technologies. The acquisition will strengthen RenovaroCube's ability to create a powerhouse for cancer diagnostics. RenovaroCube's partnerships with Oxford Nanopore and Nvidia position the company as a leader in early cancer diagnostics. The Flamingo model focuses on detecting cancer from ultra-low pass whole genome sequencing (ULP-WGS) cell-free DNA data using fragmentomics. The model achieves remarkable performance in distinguishing cancer from healthy samples. RenovaroCube invites doctors, scientists, and research institutions to join in the early research use application of their AI/machine learning platform to advance cancer diagnostics. [089ced60]